BWA
RXRX icon

Basecamp Wealth Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Basecamp Wealth Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.9K Buy
4,879
+224
+5% +$746 ﹤0.01% 856
2026
Q1 		$14.3K Hold
4,655
– – ﹤0.01% 926
2025
Q4 		$19K Buy
+4,655
New +$23.1K ﹤0.01% 806

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Basecamp Wealth Advisors's RXRX Position: Q2 2026 in Review

Basecamp Wealth Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 4.8% in Q2 2026, buying an estimated $746 and bringing the position to 4,879 shares worth $17.9K. The position accounts for ﹤0.01% of the portfolio, ranked #856.

Basecamp Wealth Advisors first reported a position in RXRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $19K in Q4 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Basecamp Wealth Advisors held 4,879 shares of Recursion Pharmaceuticals worth $17.9K as of Q2 2026.
  • Basecamp Wealth Advisors bought 224 Recursion Pharmaceuticals shares in Q2 2026, an estimated $746.
  • Recursion Pharmaceuticals made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #856 holding.
  • Basecamp Wealth Advisors first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's Recursion Pharmaceuticals position peaked at $19K in Q4 2025.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.